New Trade Alert: Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI)

 
info@mybeststockpicks.com 1-(844)-30-STOCK  
To Get Update On Mobile Text STOCKS to 67076
The #1 Newsletter for Highly Profitable Penny Stock Alerts
Our new PIck is HJLI
Hello!
 

Today we would like to provide you with a newly listed NASDAQ trade alert that could present you with upside potential.

New Trade Alert: Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI)

HJLI is a newly listed NASDAQ healthcare company that began trading a little over a month ago.

On June 5thHJLI “announced the closing of its previously announced initial public offering of 1,500,000 units, each unit consisting of one share of common stock and a warrant to purchase one share of common stock, at an initial public offering price of $5.00 per unit.”

“Gross proceeds from the IPO amount to $7,500,000 before underwriting discounts and commissions.”

HJLI specializes in “developing and manufacturing bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases.”

HJLI currently has “three product candidates”:

  • “the porcine tissue based VenoValve®, which is intended to be surgically implanted in the deep venous system of the leg to treat Chronic Venue Insufficiency”
  • “the CoreoGraft®, a bovine tissue based off the shelf conduit intended to be used for coronary artery bypass surgery”
  • the “porcine tissue based heart valve, which based upon its relatively small size and increased output, is an ideal candidate for pediatric aortic/mitral valve replacement.”

According to the company, “approximately 20 million people in the U.S. suffer from varicose veins,” a market which the VenoValve, one of the company’s three main products, addresses.

““Chronic venous insufficiency afflicts almost twice as many people as all cardiovascular diseases combined, and six times more than those with diabetes. It is one of our most prevalent diseases. However, CVD is significantly, underestimated, underdiagnosed and undertreated” Mary L. Yost, President, Sage Group Consulting”

In addition, CoreoGraft, one of the company’s products, is aiming to be utilized in “approximately 150,000 annual CABG procedures performed in the U.S.,” potentially reducing the complications associated with bypass graft harvesting which according to the company “remains the most invasive and complication prone aspect of minimally invasive bypass procedures.”

Moreover, “bypass graft failure rates” “at 10 years” are a remarkable approximate “50% fail”,according to the company.

Healthcare companies have been recently surging in 2018 with the Spider Trust Healthcare ETF, amongst others, reaching all-time highs earlier in 2018.

In addition, the S&P Biotech ETF, a subcomponent of the healthcare industry, reached all-time highs a few week ago.

Since its IPO, HJLI has experienced remarkable volatility, trading between a range of 5.64 and 3.05.

In the event that HJLI breaks out above its 20 day moving average, this could suggest increased further upside potential.  

Since the IPO, HJLI released the following news on June 20th:

Hancock Jaffe Laboratories Selects Site for First-in-Human VenoValve Study

IRVINE, Calif., June 20, 2018 (GLOBE NEWSWIRE) — Hancock Jaffe Laboratories, Inc. (HJLI) (HJLIW), a company specializing in bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases, today announced that it has selected Fundación Santa Fe de Bogotá (“FSFB”), in Bogota Columbia, as the site for first-in-human testing of its VenoValve(R) bioprosthetic medical device.   FSFB owns the 205 bed University Hospital in Bogota, which was the first hospital in Columbia to receive the distinguished Joint Commission International accreditation, and which is a research collaboration partner with John’s Hopkins Medical International.

Hancock Jaffe will now begin the process of having the protocol for the VenoValve’s first-in-human testing approved by FSFB’s research and ethics committees. No specific time frame is being announced for the approvals, however the company expects to have all necessary approvals and paperwork in place well in advance of the first-in-human testing, which it hopes will begin by the fourth quarter of this year.  As part of its ongoing VenoValve development work, the company is also preparing to begin a thirty (30) day biocompatibility study. 

Hancock Jaffe is developing the VenoValve to treat severe cases of Chronic Venous Insufficiency (“CVI”). CVI occurs when the valves in the in the veins of deep venous system of the  leg are injured or  destroyed, causing blood to pool in the lower extremities, which leads to swelling, debilitating pain, and skin ulcerations. Practitioners rate the severity of CVI based upon a system known as CEAP, which stands for Clinical-Etiology-Anatomy-Pathophysiology, which has a rating system of C0 to C6, with C4, C5, and C6 being the most severe cases.  Approximately 4.5 million people in the U.S. suffer from severe CVI and the condition results in over 700,000 hospitalizations per year. There are currently no FDA approved treatments for deep venous CVI.

HJLI presents a potentially compelling trade opportunity given that this is a newly listed NASDAQ company which could continue to attract increased interest from Wall Street as more investors become familiar with the company.

However, don’t take our word for it, make sure to do your own due diligence.

Source: PR1PR2WebsiteChartsPresentation

 

 

 

 

DISCLAIMER

The disclaimer is to be read and fully understood before using our site Mybeststockpicks.com also refered to as MBSP. This report/release/video profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. Never invest in any stock discussed on Mybeststockpicks.com or MBSP’s newsletter unless you can afford to lose your entire investment. Never listen to anyone on MBSP message boards or private messages sent by any user or member who offers any sort of financial advice. Please consult with a certified financial advisor before making any investment decisions. MBSP and any affiliates and information providers make no implied or expressed warranties on the information provided. Please verify quotes with your investment manager before making investment decisions. This is not to be construed as a solicitation to buy or sell securities. Any stock or featured companies on MBSP web site and/or newsletter involves a high degree of risk and volatility, and all investors should know that they may lose a portion or all of their investment if they decide to purchase any stock mentioned or talked about on MBSP or message boards. MBSP makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or members and does not guarantee the correctness, completeness or quality of information and statements presented on MBSP. Any such information or statements should be deemed apocryphal and opinions only. Neither MBSP, nor any of its affiliates, are registered investment advisors or broker dealers and do not make recommendations to buying, holding, or selling of any securities. MBSP simply provides a starting point for site members and viewers to compare their own thoughts against those here on the message boards at MBSP. The onus is on site members and viewers to complete their own due diligence. MBSP members and viewers should always make their own financial decisions. The accuracy and completeness of the information within any report, newsletter or on website message boards is only as reliable as the information that is provided by MBSP members and users. MBSP does not verify the information, and makes no warranty that the information is accurate. MBSP members, readers and viewers are cautioned that small and micro-cap stocks are high-risk investments and that all investment dollars can be lost. We suggest you consult a professional investment advisor before purchasing any stock. All opinions and postings expressed on MBSP web site are the opinions of MBSP members and users . All information concerning any company is provided by the members and users that create the information box on each board. MBSP recommends you use the information found here on the site and boards as an initial starting point for conducting you own research and conduct your own due diligence (also known as “DD” on any company you read about here at MBSP, in order to determine your own personal opinion of the company before investing in these or any other companies. MBSP assumes all information to be truthful and reliable. However, we cannot and do not warrant or guarantee the accuracy of this information. MBSP is NOT an Investment Advisor, Financial Planning Service or a Stock Brokerage Firm and in accordance with such MBSP is not offering investment advice or promoting any investment strategies. MBSP is not offering securities for sale or solicitation of any offer to buy or sell securities. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. On occasion, MBSP may receive compensation from a third party in relation to the companies being profiled in its Newsletters sent to our members. In such a case MBSP directly mentions such compensations at the bottom of this disclaimer along with the exact form and amount of compensation.  in relation to the companies being profiled in its Newsletters sent to our members. In such a case MBSP directly mentions such compensations at the bottom of this disclaimer along with the exact form and amount of compensation.  Mybeststockpicks.com has been compensated total of two thousand dollars by ALG LLC to perform  a two day investors awareness advertisement on HJLI Do your own research and due diligence before investing in any company. MBSP merely is providing information and is in no way or manner suggesting an investment in any company or investment opportunity. You are the investor and are making decisions for yourself. report/release/video profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.

 

2012 www.mybeststockpicks.com. All rights reserved.To Unsubscribe Click Here
Total Views: 1446 ,